/

Medtronic plc

MDT US

MDT USMedtronic plc

United States Composite

79.19

USD

+0.11

(+0.14%)

3.15EPS Dil.

25.07P/E

105.30BMarket Cap

3.47%Div. Yield

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

Medtronic plc

MDT

(United States Composite)

Recent

price

79.19

P/E

ratio

25.07

div

yld

3.47%

ROIC.AI

Legends:

Stock price

0.76

Beta (1.0 Market)

% total return 04/19

Stock

S&P500

YTD

0.15

- -

-32.61

- -

0.93

- -

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

premium

Capital Structure

FRC

•

in mil. unless spec.

Jul'24

Oct'24

Jan'24

ST Debt

premium

LT Borrowings

premium

LT Finance Leases

premium

Preferred Equity and Hybrid Capital

premium

Shares Outstanding

premium

Market Capitalization

premium

Working Capital

FRC

•

in mil. unless spec.

Jul'24

Oct'24

Jan'24

Total Current Assets

premium

Cash, Cash Equivalents & STI

premium

Accounts Receivable, Net

premium

Inventories

premium

Total Current Liabilities

premium

Payables & Accruals

premium

ST Debt

premium

Deferred Revenue

premium

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

premium

Net Income, GAAP

premium

Free Cash Flow

premium

Total Cash Common Dividend

premium

Total Equity

premium

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2022

premium

2023

premium

2024

premium

- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2022

premium

2023

premium

2024

premium

- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2022

premium

2023

premium

2024

premium

- -

Business: Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Company News

Yahoo
9 days ago
Medtronic (MDT) Falls More Steeply Than Broader Market: What Investors Need to Know

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

premium